Literature DB >> 33740991

miR-34a mimic or pre-mir-34a, which is the better option for cancer therapy? KatoIII as a model to study miRNA action in human gastric cancer cells.

Narjes Jafari1, Saeid Abediankenari2,3, Hadi Hossein-Nataj4.   

Abstract

BACKGROUND: Aberrantly expressed microRNAs play important roles in gastric tumorigenesis. However, use of miRNAs as a therapeutic option in gastric cancer still remains as a challenging problem.
METHODS: We performed transient transfection of miR-34a-5p mimic and stable transfection of pre-mir-34a into KatoIII cells. Then, we evaluated the effect of transfected miRNAs on numerous cellular and molecular processes.
RESULTS: Following transient transfection of miR-34a-5p mimic at 25 nM-a commonly used concentration-into KatoIII cells, inhibition of two target genes expression, namely Notch1 and β-catenin, was not observed, but a non-significant marginal increase of these genes was detected. No changes were detected in the percentage of apoptotic cells as well as in CD44 + and EpCAM + cells after 25 nM miR-34a-5p mimic transfection. Interestingly, stable transfection of pre-mir-34a into KatoIII cells (named as KatoIII-pGFPC1-34a cells) caused a significant repression in β-catenin protein and Notch1 mRNA levels (p < 0.05 and p < 0.01, respectively) relative to equivalent control (KatoIII- pGFPC1-empty cells). The percentage of CD44 + cells in the KatoIII-pGFPC1-34a cells (< 40%) was significantly lower than that in control cells (~ 95%) (p < 0.05). An increase of ~ 3.5% in apoptotic cells and a slower proliferation rate were detected in KatoIII-pGFPC1-34a cells.
CONCLUSIONS: Our study revealed that the effect of miR mimic in target gene repression can be dependent to its concentration as well as to the cell type. Meanwhile, our findings further support a regulatory function for pre-miRNAs in target repression and will help to develop effective therapeutic strategies in cancer treatment.

Entities:  

Keywords:  Cancer stem cells; Gastric cancer; MicroRNA-34a; Precursor miRNA; Transfection

Year:  2021        PMID: 33740991     DOI: 10.1186/s12935-021-01872-5

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  44 in total

1.  The potential functions of primary microRNAs in target recognition and repression.

Authors:  Robin Deis Trujillo; Si-Biao Yue; Yujie Tang; William E O'Gorman; Chang-Zheng Chen
Journal:  EMBO J       Date:  2010-08-31       Impact factor: 11.598

2.  [Morphofunctional criteria for the selection of patients with ischemic heart disease and associated arterial hypertension for surgical treatment].

Authors:  O F Gor'kavaia; Iu I Buziashvili; L M Fitileva; V P Kertsman; T Iu Kuznetsova
Journal:  Grudn Khir       Date:  1989 Nov-Dec

Review 3.  Immunotherapy in gastric cancer.

Authors:  Satoko Matsueda; David Y Graham
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 4.  MicroRNAs and cancer stem cells: the sword and the shield.

Authors:  X Sun; X Jiao; T G Pestell; C Fan; S Qin; E Mirabelli; H Ren; R G Pestell
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

5.  MicroRNA-206 suppresses gastric cancer cell growth and metastasis.

Authors:  Jun Ren; Hui-Jie Huang; Yu Gong; Shen Yue; Li-Ming Tang; Steven Y Cheng
Journal:  Cell Biosci       Date:  2014-05-05       Impact factor: 7.133

6.  Expression patterns of seven key genes, including β-catenin, Notch1, GATA6, CDX2, miR-34a, miR-181a and miR-93 in gastric cancer.

Authors:  Narjes Jafari; Saeid Abediankenari; Zahra Hosseini-Khah; Seyed Mohammad Valizadeh; Zhila Torabizadeh; Ehsan Zaboli; Maryam Ghasemi; Hafez Fakheri; Vahid Hosseini; Ramin Shekarriz; Alireza Rafiei; Hossein Asgarian-Omran; Fatemeh Abedian
Journal:  Sci Rep       Date:  2020-07-23       Impact factor: 4.379

Review 7.  MicroRNAs in pancreatic cancer diagnosis and therapy.

Authors:  Robert Słotwiński; Gustaw Lech; Sylwia Małgorzata Słotwińska
Journal:  Cent Eur J Immunol       Date:  2018-10-30       Impact factor: 2.085

8.  Pre-miRNA loop nucleotides control the distinct activities of mir-181a-1 and mir-181c in early T cell development.

Authors:  Gwen Liu; Hyeyoung Min; Sibiao Yue; Chang-Zheng Chen
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

9.  Lauren classification and individualized chemotherapy in gastric cancer.

Authors:  Junli Ma; Hong Shen; Linda Kapesa; Shan Zeng
Journal:  Oncol Lett       Date:  2016-03-16       Impact factor: 2.967

10.  A common molecular signature of intestinal-type gastric carcinoma indicates processes related to gastric carcinogenesis.

Authors:  Renata Binato; Everton Cruz Santos; Mariana Boroni; Samia Demachki; Paulo Assumpção; Eliana Abdelhay
Journal:  Oncotarget       Date:  2017-12-27
View more
  6 in total

Review 1.  MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.

Authors:  Mamta Panda; Elora Kalita; Satyendra Singh; Ketan Kumar; Abhishek Rao; Vijay Kumar Prajapati
Journal:  Life Sci       Date:  2022-07-01       Impact factor: 6.780

2.  MiR-199a-3p Restrains Foaming and Inflammation by Regulating RUNX1 in Macrophages.

Authors:  Mingxin Liu; Yiming Cao; Yu Hu; Zhe Zhang; Sitong Ji; Linyang Shi; Guizhou Tao
Journal:  Mol Biotechnol       Date:  2022-04-18       Impact factor: 2.860

Review 3.  The Challenges and Opportunities in the Development of MicroRNA Therapeutics: A Multidisciplinary Viewpoint.

Authors:  Mohammad Yahya Momin; Ravinder Reddy Gaddam; Madeline Kravitz; Anisha Gupta; Ajit Vikram
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

Review 4.  Targeting the microRNA-34a as a Novel Therapeutic Strategy for Cardiovascular Diseases.

Authors:  Cun-Cun Hua; Xin-Ming Liu; Li-Rong Liang; Le-Feng Wang; Jiu-Chang Zhong
Journal:  Front Cardiovasc Med       Date:  2022-01-27

5.  Ubiquitin-associated protein 2 like (UBAP2L) enhances growth and metastasis of gastric cancer cells.

Authors:  Sihan Lin; Zhiyong Yan; Qiaofei Tang; Shuang Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Downregulation of TNFR2 decreases survival gene expression, promotes apoptosis and affects the cell cycle of gastric cancer cells.

Authors:  Ana Flávia Teixeira Rossi; Fernanda da Silva Manoel-Caetano; Joice Matos Biselli; Ágata Silva Cabral; Marilia de Freitas Calmon Saiki; Marcelo Lima Ribeiro; Ana Elizabete Silva
Journal:  World J Gastroenterol       Date:  2022-06-28       Impact factor: 5.374

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.